Restoring p53 function in cancer: Novel therapeutic approaches for applying the brakes to tumorigenesis

Recent Patents on Anti-Cancer Drug Discovery

Volumn 5, Issue 1, 2010, Pages 1-13

  Di Cintio, Alessandra ^a   Di Gennaro, Elena ^a   Budillon, Alfredo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Gene therapy; MDM2; Molecular targeted drug; P53; Small molecules

Indexed keywords

2 HYDROXYMETHIL 2 METHOXYMETHYLAZABICYCLO[2.2.2]OCTAN 3 ONE; 2,2 BIS(HYDROXYMETHIL) 1 AZABICYCLO[2.2.2]OCTAN 3 ONE; ADVEXIN; ANTINEOPLASTIC AGENT; ATM PROTEIN; CBS 9106; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; FOLIC ACID ANTAGONIST; GEMCITABINE; GENDICINE; IMIDAZOLINE; JNJ 26854165; MI 219; N (ACETOXYMETHYL)MALEIMIDE; N (PROPOXYMETHYL)MALEMIDE; NON PEPTIDIC SMALL MOLECULE; NUTLIN 3; ONYX 015; PARTHENOLIDE; PEPTIDOMIMETIC AGENT; PHENETHYL ISOTHIOCYANATE; PNC 27; PROTEIN MDM2; PROTEIN MDMX; PROTEIN P53; TDP 521252; TDP 665759; TENOVIN 6; UNCLASSIFIED DRUG; UNINDEXED DRUG; FURAN DERIVATIVE; NSC 652287;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL CYCLE ARREST; CELL STRESS; DRUG MECHANISM; DRUG TARGETING; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE FUNCTION; GENE INACTIVATION; GENE MUTATION; GENE REPLACEMENT THERAPY; HEAD AND NECK TUMOR; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTO ONCOGENE; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; BIOLOGICAL MODEL; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; METABOLISM; METHODOLOGY; MUTATION; NEOPLASM;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; DRUG SCREENING ASSAYS, ANTITUMOR; FURANS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; HUMANS; MODELS, BIOLOGICAL; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77649256273     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489210789702172     Document Type: Article

References (105)

1. Moll UM. The Role of p63 and p73 in tumor formation and progression: Coming of age toward clinical usefulness. Commentary re: Koga F, Kawakami S, Fujii Y, et al. Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clin Cancer Res 2003; 9: 5501-5507. and Puig P, Capodieci P, Drobnjak M, et al. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder Cancer. Clin Cancer Res 2003; 9: 5642-5651. Comment in: 2003; 9: 5437-5441.
2. Sookraj K, Adler V, WEYazdi E, et al. p53-derived peptide targets a novel death pathway inducing selective necrosis in cancer cells. AACR Annual Meeting, Denver, USA April 2009.
3. Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 13: 4107-4114.
4. Picksley SM, Vojtesek B, Sparks A, Lane DP. Immunochemical analysis of the interaction of p53 with MDM2; fine mapping of the MDM2 binding site on p53 using synthetic peptides. Oncogene 1994; 9: 2523-2529.
5. Shangary S, Wang S. Targeting the MDM2-p53 interaction for cancer therapy. Clin Cancer Res 2008; 14: 5318-5324.
6. Toledo F, Wahl GM. MDM2 and MDM4: p53 regulators as targets in anticancer therapy. Int J Biochem Cell Biol 2007; 39: 1476-1482.
7. Wade M, Wahl GM. Targeting Mdm2 and Mdmx in cancer therapy: Better living through medicinal chemistry? Mol Cancer Res 2009; 7: 1-11.
8. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 2003; 278: 13595-13598.
9. Vousden KH. p53: Death star. Cell 2000; 103: 691-694.
10. Siliciano JD, Canman CE, Taya Y, et al. DNA damage induces phosphorylation of the amino terminus of p53. Genes Dev 1997; 11: 3471-3481.
11. Chao C, Saito S, Anderson CW, Appella E, Xu Y. Phosphorylation of murine p53 at ser-18 regulates the p53 responses to DNA damage. Proc Natl Acad Sci USA 2000; 97: 11936-11941.
12. Saito S, Goodarzi AA, Higashimoto Y, et al. ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation. J Biol Chem 2002; 277: 12491-12494.
13. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair (Amst) 2004; 3: 889-900.
14. Ford JM. Regulation of DNA damage recognition and nucleotide excision repair: Another role for p53. Mutat Res 2005; 577: 195-202.
15. Harris SL, Levine AJ. The p53 pathway: Positive and negative feedback loops. Oncogene 2005; 24: 2899-2908.
16. Lee MH, Lozano G. Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins. Semin Cancer Biol 2006; 16: 225-234.
17. Hermeking H, Lengauer C, Polyak K, et al. 14-3-3 sigma is a p53-regulated inhibitor of G2/M progression. Mol Cell 1997; 1: 3-11.
18. Maximov G, Maximov K. The role pf p53 tumor-suppressor protein in apoptosis and cancerogenesis. Biotechnol Biotechol Equip 2008; 22: 664-668.
19. Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis - the p53 network. J Cell Sci 2003; 116: 4077-4085.
20. Flores ER, Tsai KY, Crowley D, et al. p63 And p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002; 416: 560-564.
21. Marin MC, Jost CA, Brooks LA, et al. A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat Genet 2000; 25: 47-54.
22. Bergamaschi D, Gasco M, Hiller L, et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 2003; 3: 387-402.
23. Ravi R, Mookerjee B, Bhujwalla ZM, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 2000; 14: 34-44.
24. Khromova NV, Kopnin PB, Stepanova EV, Agapova LS, Kopnin BP. p53 hot-spot mutants increase tumor vascularization via ROS-mediated activation of the HIF1/VEGF-A pathway. Cancer Lett 2009; 276: 143-151.
25. Ren B, Yee KO, Lawler J, Khosravi-Far R. Regulation of tumor angiogenesis by thrombospondin-1. Biochim Biophys Acta 2006; 1765: 178-188.
26. Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch. Proc Natl Acad Sci USA 2006; 103: 16266-16271.
27. Adorno M, Cordenonsi M, Montagner M, et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell, 2009; 137: 87-98.
28. Guo X, Mills AA. p63, cellular senescence and tumor development. Cell Cycle 2007; 6: 305-311.
29. Artandi SE, Attardi LD. Pathways connecting telomeres and p53 in senescence, apoptosis, and cancer. Biochem Biophys Res Commun 2005; 331: 881-890.
30. Papazoglu C, Mills AA. p53: At the crossroad between cancer and ageing. J Pathol 2007; 211: 124-133.
31. Fridman AL, Tainsky MA. Critical pathways in cellular senescence and immortalization revealed by gene expression profiling. Oncogene 2008; 27: 5975-5987.
32. Shay JW, Pereira-Smith OM, Wright WE. A role for both RB and p53 in the regulation of human cellular senescence. Exp Cell Res 1991; 196: 33-39.
33. Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004; 23: 6445-6470.
34. Gonzalez KD, Noltner KA, Buzin CH, et al. Beyond Li Fraumeni Syndrome: Clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009; 27: 1250-1256.
35. Suad O, Rozenberg H, Brosh R, et al. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol 2009; 385: 249-265.
36. Soussi T, Lozano G. p53 mutation heterogeneity in cancer. Biochem Biophys Res Commun 2005; 331: 834-842.
37. Ludwig RL, Bates S, Vousden KH. Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. Mol Cell Biol 1996; 16: 4952-4960.
38. Smith PD, Crossland S, Parker G, et al. Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions. Oncogene 1999; 18: 2451-2459.
39. Cadwell C, Zambetti GP. The effects of wild-type p53 tumor suppressor activity and mutant p53 gain-of-function on cell growth. Gene 2001; 277: 15-30.
40. Meulmeester E, Pereg Y, Shiloh Y, Jochemsen AG. ATM-mediated phosphorylations inhibit Mdmx/Mdm2 stabilization by HAUSP in favor of p53 activation. Cell Cycle 2005; 4: 1166-1170.
41. Wattel E, Preudhomme C, Hecquet B, et al. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
42. Lin K, Sherrington PD, Dennis M, et al. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002; 100: 1404-1409.
43. Nelson WG, Kastan MB. DNA strand breaks: The DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-1823.
44. Zheng M, Wang H, Zhang H, et al. The influence of the p53 gene on the in vitro chemosensitivity of colorectal cancer cells. J Cancer Res Clin Oncol 1999; 125: 357-360.
45. Pugacheva EN, Ivanov AV, Kravchenko JE, et al. Novel gain of function activity of p53 mutants: Activation of the dUTPase gene expression leading to resistance to 5-fluorouracil. Oncogene 2002; 21: 4595-4600.
46. Benhattar J, Cerottini JP, Saraga E, Metthez G, Givel JC. p53 mutations as a possible predictor of response to chemotherapy in metastatic colorectal carcinomas. Int J Cancer 1996; 69: 190-192.
47. Giovannetti E, Backus HH, Wouters D, et al. Changes in the status of p53 affect drug sensitivity to thymidylate synthase (TS) inhibitors by altering TS levels. Br J Cancer 2007; 96: 769-775.
48. Righetti SC, Della Torre G, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996; 56: 689-693.
49. Darcy KM, Brady WE, McBroom JW, et al. Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers. A Gynecologic Oncology Group study. Gynecol Oncol 2008; 111: 487-495.
50. Ueno Y, Enomoto T, Otsuki Y, et al. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. Cancer Lett 2006; 241: 289-300.
51. Zangen R, Ratovitski E, Sidransky D. DeltaNp63alpha levels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4: 1313-1315.
52. Leong CO, Vidnovic N, DeYoung MP, Sgroi D, Ellisen LW. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380.
53. Lavarino C, Pilotti S, Oggionni M, et al. p53 gene status and response to platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma. J Clin Oncol 2000; 18: 3936-3945.
54. Kupryjanczyk J, Kraszewska E, Ziolkowska-Seta I, et al. TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study. BMC Cancer 2008; 8: 27.
55. Crul M, van Waardenburg RC, Bocxe S, et al. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin. Biochem Pharmacol 2003; 65: 275-282.
56. Gandhi V, Legha J, Chen F, Hertel LW, Plunkett W. Excision of 2',2'-difluorodeoxycytidine (gemcitabine) monophosphate residues from DNA. Cancer Res 1996; 56: 4453-4459.
57. Cascallo M, Calbo J, Gelpi JL, Mazo A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther 2000; 7: 545-556.
58. Bouchet BP, de Fromentel CC, Puisieux A, Galmarini CM. p53 as a target for anti-cancer drug development. Crit Rev Oncol Hematol 2006; 58: 190-207.
59. Roth, J. A., Mukhopadhyay, T., Tainsky, M. A.: US6998117 (2006).
60. Senzer N, Nemunaitis J. A review of contusugene ladenovec (Advexin) p53 therapy. Curr Opin Mol Ther 2009; 11: 54-61.
61. Peng Z. Current status of gendicine in China: Recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027.
62. Russo A, Terrasi M, Agnese V, Santini D, Bazan V. Apoptosis: A relevant tool for anticancer therapy. Ann Oncol 2006; 17 (Suppl 7): vii115-123.
63. Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat Med 2000; 6: 1128-1133.
64. Geoerger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764-772.
65. Alemany R. Cancer selective adenoviruses. Mol Aspects Med 2007; 28: 42-58.
66. Oin, X.: US5869040 (1999).
67. Ramesh, R.: US20090004145 (2009).
68. Domling A. Small molecular weight protein-protein interaction antagonists: An insurmountable challenge? Curr Opin Chem Biol 2008; 12: 281-291.
69. Wang W, El-Deiry WS. Restoration of p53 to limit tumor growth. Curr Opin Oncol 2008; 20: 90-96.
70. Bykov VJ, Issaeva N, Shilov A, et al. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 2002; 8: 282-288.
71. Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Mol Cancer Ther 2005; 4: 901-909.
72. Rehman A, Chahal MS, Tang X, et al. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Breast Cancer Res 2005; 7: R765-774.
73. Bykov VJ, Zache N, Stridh H, et al. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Oncogene 2005; 24: 3484-3491.
74. Bykov VJ, Issaeva N, Zache N, et al. Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs. J Biol Chem 2005; 280: 30384-30391.
75. Lambert JM, Gorzov P, Veprintsev DB, et al. PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009; 15: 376-388.
76. Zache N, Lambert JM, Rokaeus N, et al. Mutant p53 targeting by the low molecular weight compound STIMA-1. Mol Oncol 2008; 2: 70-80.
77. Wang K, Doemling A. Selective and dual action p53/mdm2/mdm4 antagonists. AACR Annual Meeting, Denver, USA April 2009.
78. Thompson T, Tovar C, Yang H, et al. Phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. J Biol Chem 2004; 279: 53015-53022.
79. Tovar C, Rosinski J, Filipovic Z, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: Implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888-1893.
80. Vassilev LT, Vu BT, Graves B, et al. in vivo Activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004; 303: 844-848.
81. Sarek G, Kurki S, Enback J, et al. Reactivation of the p53 pathway as a treatment modality for KSHV-induced lymphomas. J Clin Invest 2007; 117: 1019-1028.
82. Teodoro JG, Evans SK, Green MR. Inhibition of tumor angiogenesis by p53: A new role for the guardian of the genome. J Mol Med 2007; 85: 1175-1186.
83. LaRusch GA, Jackson MW, Dunbar JD, et al. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res 2007; 67: 450-454.
84. Hu B, Gilkes DM, Farooqi B, Sebti SM, Chen J. MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. J Biol Chem 2006; 281: 33030-33035.
85. Shangary S, Ding K, Qiu S, et al. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol Cancer Ther 2008; 7: 1533-1542.
86. Shangary S, Qin D, McEachern D, et al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc Natl Acad Sci USA 2008; 105: 3933-3938.
87. Koblish HK, Zhao S, Franks CF, et al. Benzodiazepinedione inhibitors of the Hdm2: p53 Complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol Cancer Ther 2006; 5: 160-169.
88. Chen D, Zhang J, Li M, et al. RYBP stabilized p53 by modulating MDM2. AACR Annual Meeting, Denver, USA April 2009.
89. Lain S, Hollick JJ, Campbell J, et al. Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator. Cancer Cell 2008; 13: 454-463.
90. Skobeleva N, Kalinski C, Ross G, et al. NXN compounds - a new class of HDM2-p53 interaction inhibitors that exhibit tight binding to HDM2 and inhibit malignant phenotypes in cancer cells with wild type p53 in cell based assays and in animal models. AACR Annual Meeting, Denver, USA April 2009.
91. Sakakibara K, Saito N, Sato T, et al. A novel anti-cancer compound CBS9106 activates p53 and induces apoptosis in acute lynphoblastic leukemia and multiple myeloma cells. AACR Annual Meeting, Denver, USA April 2009.
92. Yang, A., Mckeon, F.: US20080200664 (2008).
93. Arts J, Smans K, Andries L, et al. Preclinical and clinical pharmacodynamic activity of JNJ-26854165: A novel hdm2 antagonist in clinical development. AACR Annual Meeting, Denver, USA April 2009.
94. Issaeva N, Bozko P, Enge M, et al. Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 2004; 10: 1321-1328.
95. Espinoza-Fonseca LM. Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer. Theor Biol Med Model 2005; 2: 38.
96. Krajewski M, Ozdowy P, D'Silva L, Rothweiler U, Holak TA. NMR indicates that the small molecule RITA does not block p53-MDM2 binding in vitro. Nat Med 2005; 11: 1135-1136; author reply 1136-1137.
97. Enge M, Bao W, Hedstrom E, et al. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009; 15: 171-183.
98. Grinkevich VV, Nikulenkov F, Shi Y, et al. Ablation of key oncogenic pathways by RITA-reactivated p53 is required for efficient apoptosis. Cancer Cell 2009; 15: 441-453.
99. Yang J, Ahmed A, Poon E, et al. Small-molecule activation of p53 blocks hypoxia-inducible factor 1 alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia. Mol Cell Biol 2009; 29: 2243-2253.
100. Mukhopadhyay, T., Roth, J.A.: US5958892 (1999).
101. Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer 2004; 4: 793-805.
102. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol 2008; 153: 657-668.
103. Di Gennaro E, Bruzzese F, Pepe S, et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009; 8: 782-791.
104. Gopal YN, Chanchorn E, Van Dyke MW. Parthenolide promotes the ubiquitination of MDM2 and activates p53 cellular functions. Mol Cancer Ther 2009; 8: 552-562.
105. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Oncogene 2008; 27: 6571-6580.